Status:

COMPLETED

Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis

Lead Sponsor:

Instituto Nacional de Cardiologia Ignacio Chavez

Conditions:

End Stage Renal Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This is a double blind randomized controlled study to evaluate the effect of aldactone on peritoneal fibrosis on incident peritoneal dialysis patients. The study would include a total of 40 incident p...

Eligibility Criteria

Inclusion

  • Age \> 18
  • Hospitalized for peritoneal catheter placement for peritoneal dialysis

Exclusion

  • Pregnancy
  • Hiperkalemia (K\> 5.5meq/l)
  • Intolerance to spironolactone

Key Trial Info

Start Date :

July 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2012

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00865449

Start Date

July 1 2008

End Date

March 1 2012

Last Update

October 25 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Instituto Nacional de Cardiologia Ignacio Chavez

Mexico City, Mexico City, Mexico, 14080

Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis | DecenTrialz